Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: cross-sectional and prospective studies and meta-analyses of 75,000 cases and 93,000 controls

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: cross-sectional and prospective studies and meta-analyses of 75,000 cases and 93,000 controls. / Zacho, Jeppe; Yazdanyar, Shiva; Bojesen, Stig E; Tybjærg-Hansen, Anne; Nordestgaard, Børge G.

In: International Journal of Cancer, Vol. 128, No. 3, 2011, p. 644-52.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Zacho, J, Yazdanyar, S, Bojesen, SE, Tybjærg-Hansen, A & Nordestgaard, BG 2011, 'Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: cross-sectional and prospective studies and meta-analyses of 75,000 cases and 93,000 controls', International Journal of Cancer, vol. 128, no. 3, pp. 644-52. https://doi.org/10.1002/ijc.25375

APA

Zacho, J., Yazdanyar, S., Bojesen, S. E., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2011). Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: cross-sectional and prospective studies and meta-analyses of 75,000 cases and 93,000 controls. International Journal of Cancer, 128(3), 644-52. https://doi.org/10.1002/ijc.25375

Vancouver

Zacho J, Yazdanyar S, Bojesen SE, Tybjærg-Hansen A, Nordestgaard BG. Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: cross-sectional and prospective studies and meta-analyses of 75,000 cases and 93,000 controls. International Journal of Cancer. 2011;128(3):644-52. https://doi.org/10.1002/ijc.25375

Author

Zacho, Jeppe ; Yazdanyar, Shiva ; Bojesen, Stig E ; Tybjærg-Hansen, Anne ; Nordestgaard, Børge G. / Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: cross-sectional and prospective studies and meta-analyses of 75,000 cases and 93,000 controls. In: International Journal of Cancer. 2011 ; Vol. 128, No. 3. pp. 644-52.

Bibtex

@article{9a8659bf7940486f93c84745bf62017a,
title = "Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: cross-sectional and prospective studies and meta-analyses of 75,000 cases and 93,000 controls",
abstract = "Global DNA hypomethylation associates with development of cancer. DNA hypomethylation also associates with hyperhomocysteinemia and MTHFR c.677C>T homozygosity, both of which may associate with increased risk of cancer. We tested the putative association of hyperhomocysteinemia with cancer and the association of the MTHFR c.677TC>T variant with hyperhomocysteinemia and with cancer. We performed a cross-sectional study of 5,949 Danish general population adults, a prospective study of 9,235 Danish general population adults with up to 60 years of registry surveillance, and meta-analyses of 231 studies including 74,671 cases and 93,344 controls. Cross-sectionally, plasma homocysteine levels were 12.9 and 11.6 µmol/L in those with and without cancer (p <0.0001). age age-adjusted and any cancer for homocysteine however, in increased levels odds ratio those with>12.4 versus <9.4 µmol 1.0. 11.7 14.7 and c.677c cancer-free did differ from homocysteine in l levels mthfr not participants, plasma were>T homozygtes and noncarriers (p <0.0001). and any c.677c cancer for hazard in mthfr prospectively, ratios subtypes>T homozygotes versus noncarriers did not differ from 1.0. However, in meta-analyses odds ratio for MTHFR c.677C>T homozygotes versus noncarriers were 1.07 (95{\%} CI: 1.01-1.12) for any cancer, 1.77 (1.17-2.68) for esophagus cancer, 1.40 (1.19-1.66) for gastric cancer and 0.85 (0.77-0.94) for colorectal cancer. Increased plasma homocysteine levels are not associated with an increased age-adjusted risk of any cancer. However, MTHFR c.677C>T homozygosity with lifelong hyperhomocysteinemia and hence hypomethylation associate with increased risk of esophagus and gastric cancer, and with decreased risk of colorectal cancer.",
author = "Jeppe Zacho and Shiva Yazdanyar and Bojesen, {Stig E} and Anne Tybj{\ae}rg-Hansen and Nordestgaard, {B{\o}rge G}",
year = "2011",
doi = "http://dx.doi.org/10.1002/ijc.25375",
language = "English",
volume = "128",
pages = "644--52",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "JohnWiley & Sons, Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: cross-sectional and prospective studies and meta-analyses of 75,000 cases and 93,000 controls

AU - Zacho, Jeppe

AU - Yazdanyar, Shiva

AU - Bojesen, Stig E

AU - Tybjærg-Hansen, Anne

AU - Nordestgaard, Børge G

PY - 2011

Y1 - 2011

N2 - Global DNA hypomethylation associates with development of cancer. DNA hypomethylation also associates with hyperhomocysteinemia and MTHFR c.677C>T homozygosity, both of which may associate with increased risk of cancer. We tested the putative association of hyperhomocysteinemia with cancer and the association of the MTHFR c.677TC>T variant with hyperhomocysteinemia and with cancer. We performed a cross-sectional study of 5,949 Danish general population adults, a prospective study of 9,235 Danish general population adults with up to 60 years of registry surveillance, and meta-analyses of 231 studies including 74,671 cases and 93,344 controls. Cross-sectionally, plasma homocysteine levels were 12.9 and 11.6 µmol/L in those with and without cancer (p <0.0001). age age-adjusted and any cancer for homocysteine however, in increased levels odds ratio those with>12.4 versus <9.4 µmol 1.0. 11.7 14.7 and c.677c cancer-free did differ from homocysteine in l levels mthfr not participants, plasma were>T homozygtes and noncarriers (p <0.0001). and any c.677c cancer for hazard in mthfr prospectively, ratios subtypes>T homozygotes versus noncarriers did not differ from 1.0. However, in meta-analyses odds ratio for MTHFR c.677C>T homozygotes versus noncarriers were 1.07 (95% CI: 1.01-1.12) for any cancer, 1.77 (1.17-2.68) for esophagus cancer, 1.40 (1.19-1.66) for gastric cancer and 0.85 (0.77-0.94) for colorectal cancer. Increased plasma homocysteine levels are not associated with an increased age-adjusted risk of any cancer. However, MTHFR c.677C>T homozygosity with lifelong hyperhomocysteinemia and hence hypomethylation associate with increased risk of esophagus and gastric cancer, and with decreased risk of colorectal cancer.

AB - Global DNA hypomethylation associates with development of cancer. DNA hypomethylation also associates with hyperhomocysteinemia and MTHFR c.677C>T homozygosity, both of which may associate with increased risk of cancer. We tested the putative association of hyperhomocysteinemia with cancer and the association of the MTHFR c.677TC>T variant with hyperhomocysteinemia and with cancer. We performed a cross-sectional study of 5,949 Danish general population adults, a prospective study of 9,235 Danish general population adults with up to 60 years of registry surveillance, and meta-analyses of 231 studies including 74,671 cases and 93,344 controls. Cross-sectionally, plasma homocysteine levels were 12.9 and 11.6 µmol/L in those with and without cancer (p <0.0001). age age-adjusted and any cancer for homocysteine however, in increased levels odds ratio those with>12.4 versus <9.4 µmol 1.0. 11.7 14.7 and c.677c cancer-free did differ from homocysteine in l levels mthfr not participants, plasma were>T homozygtes and noncarriers (p <0.0001). and any c.677c cancer for hazard in mthfr prospectively, ratios subtypes>T homozygotes versus noncarriers did not differ from 1.0. However, in meta-analyses odds ratio for MTHFR c.677C>T homozygotes versus noncarriers were 1.07 (95% CI: 1.01-1.12) for any cancer, 1.77 (1.17-2.68) for esophagus cancer, 1.40 (1.19-1.66) for gastric cancer and 0.85 (0.77-0.94) for colorectal cancer. Increased plasma homocysteine levels are not associated with an increased age-adjusted risk of any cancer. However, MTHFR c.677C>T homozygosity with lifelong hyperhomocysteinemia and hence hypomethylation associate with increased risk of esophagus and gastric cancer, and with decreased risk of colorectal cancer.

U2 - http://dx.doi.org/10.1002/ijc.25375

DO - http://dx.doi.org/10.1002/ijc.25375

M3 - Journal article

VL - 128

SP - 644

EP - 652

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -

ID: 40184948